Orographic Financial Advisors LLC Purchases Shares of 4,999 AbbVie Inc. $ABBV

Orographic Financial Advisors LLC acquired a new position in shares of AbbVie Inc. (NYSE:ABBV) in the 1st quarter, Holdings Channel reports. The institutional investor acquired 4,999 shares of the company’s stock, valued at approximately $1,087,000.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Bank of Jackson Hole Trust increased its holdings in shares of AbbVie by 0.6% during the fourth quarter. Bank of Jackson Hole Trust now owns 7,213 shares of the company’s stock worth $1,648,000 after buying an additional 44 shares in the last quarter. Eclectic Associates Inc. ADV grew its position in AbbVie by 0.8% during the 4th quarter. Eclectic Associates Inc. ADV now owns 5,852 shares of the company’s stock worth $1,337,000 after acquiring an additional 45 shares during the last quarter. Imprint Wealth LLC grew its position in AbbVie by 56.2% during the 4th quarter. Imprint Wealth LLC now owns 125 shares of the company’s stock worth $29,000 after acquiring an additional 45 shares during the last quarter. Dogwood Wealth Management LLC increased its holdings in AbbVie by 10.8% during the 4th quarter. Dogwood Wealth Management LLC now owns 473 shares of the company’s stock valued at $108,000 after purchasing an additional 46 shares in the last quarter. Finally, Quantum Private Wealth LLC increased its holdings in AbbVie by 2.0% during the 4th quarter. Quantum Private Wealth LLC now owns 2,376 shares of the company’s stock valued at $543,000 after purchasing an additional 46 shares in the last quarter. Institutional investors and hedge funds own 70.23% of the company’s stock.

More AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: The European Commission approved RINVOQ® for severe alopecia areata in adults and adolescents aged 12 and older. The Phase 3 program demonstrated statistically significant scalp, eyebrow, and eyelash hair regrowth, including complete scalp regrowth for some patients. The approval expands RINVOQ’s commercial opportunity in Europe. RINVOQ alopecia areata approval
• Positive Sentiment: RINVOQ also received EU approval for non-segmental vitiligo, making it the first and only systemic treatment approved for that condition in the region. The decision was supported by positive Phase 3 repigmentation data and could further diversify RINVOQ growth. RINVOQ vitiligo approval
• Positive Sentiment: AbbVie began a first-in-human Phase 1 trial of ABBV-859, providing an early-stage pipeline catalyst. The program is not expected to affect near-term earnings, but investors may view it as evidence of continued investment in long-term growth. ABBV-859 Phase 1 trial
• Positive Sentiment: Unusually heavy call-option buying and a modest increase in an analyst’s 2027 earnings forecast indicate that some traders and analysts remain bullish on AbbVie’s longer-term earnings outlook.
• Neutral Sentiment: Allergan Aesthetics will hold its annual JUVÉDERM® Day on August 19, supporting consumer engagement and the aesthetics franchise, although the promotional event is unlikely to materially change near-term financial results. JUVÉDERM Day announcement
• Neutral Sentiment: Investors are also focused on AbbVie’s second-quarter earnings report due July 31. A slight reduction in one 2026 earnings estimate was offset by a higher 2027 forecast, leaving expectations mixed ahead of the report.
• Negative Sentiment: AbbVie’s proposed acquisition of Apogee Therapeutics faces an investigation into the deal’s price and transaction process. While the review does not establish wrongdoing, it introduces regulatory and execution uncertainty around the transaction. Apogee transaction investigation
• Negative Sentiment: After a strong multi-year rally, valuation concerns and potential profit-taking may be pressuring ABBV, particularly with the shares trading near their 52-week high and at a rich earnings multiple.

Wall Street Analyst Weigh In

A number of research firms have commented on ABBV. Royal Bank Of Canada boosted their price objective on AbbVie from $260.00 to $280.00 and gave the stock an “outperform” rating in a research note on Friday, July 10th. Cantor Fitzgerald lifted their price target on AbbVie from $240.00 to $265.00 and gave the company an “overweight” rating in a report on Monday, July 6th. Wells Fargo & Company upped their price target on shares of AbbVie from $260.00 to $295.00 and gave the stock an “overweight” rating in a research report on Friday, July 10th. BMO Capital Markets increased their price objective on shares of AbbVie from $258.00 to $300.00 and gave the stock an “outperform” rating in a report on Monday, July 13th. Finally, Morgan Stanley raised their price objective on shares of AbbVie from $270.00 to $278.00 and gave the company an “overweight” rating in a research report on Thursday, April 30th. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $269.29.

AbbVie Trading Down 2.2%

Shares of NYSE:ABBV opened at $257.57 on Friday. AbbVie Inc. has a 1-year low of $187.62 and a 1-year high of $267.47. The stock has a market capitalization of $455.07 billion, a P/E ratio of 126.88, a P/E/G ratio of 0.87 and a beta of 0.30. The business has a 50-day moving average price of $238.39 and a two-hundred day moving average price of $223.86.

AbbVie (NYSE:ABBV) last issued its earnings results on Wednesday, April 29th. The company reported $2.65 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.59 by $0.06. The company had revenue of $15 billion for the quarter, compared to analyst estimates of $14.72 billion. AbbVie had a net margin of 5.79% and a negative return on equity of 576.45%. The company’s revenue for the quarter was up 12.4% on a year-over-year basis. During the same quarter last year, the firm earned $2.46 EPS. As a group, equities analysts predict that AbbVie Inc. will post 14.14 EPS for the current year.

AbbVie Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, August 14th. Shareholders of record on Wednesday, July 15th will be paid a $1.73 dividend. The ex-dividend date of this dividend is Wednesday, July 15th. This represents a $6.92 dividend on an annualized basis and a yield of 2.7%. AbbVie’s dividend payout ratio (DPR) is presently 340.89%.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.